Lilly’s Kisunla Postmarketing Studies Include Maintenance Dosing, But No Safety Trial

Lilly must conduct registry-based and retrospective cohort studies, similar to those required for Eisai/Biogen’s Leqembi, to assess the risks of ARIA and intracerebral hemorrhage with donanemab, but there is no additional requirement for a safety-focused clinical trial.